PALI - Palisade Bio Forward P/S Multiple

Patents for LB1148 and stringent FDA oversight create significant barriers to entry for competitors. The application of automated enzyme synthesis increases drug purity, as evidenced by the forward P/S trend; here 397.10 reflects the latest metric level. The implementation of software robots for clinical trial data analysis will provide Palisade Bio, Inc. (PALI) with a further technological leap in the treatment of gastrointestinal inflammation.

PALI palisadebio.com: Market Cap to Expected Sales Ratio in the range 05/21/2023 - 11/13/2026

palisadebio.com - analytical breakdowns and key metrics (PALI)

- market price and analyst price targets:

Price Chart Palisade Bio, Inc.|PALI - Price Target Chart

- market capitalization statistics:

Market Capitalization Palisade Bio, Inc.|PALI - Company Buyout Price

- issuer book value statistics:

Net Assets per Single Share Palisade Bio|PALI - Book Valuation of Business|Market Capitalization to Book Value Ratio palisadebio.com|PALI - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

PALI - Net Financial Result|Expected Profit Palisade Bio, Inc.|PALI - Market Cap to Earnings|Projected Price to Earnings Palisade Bio, Inc.|PALI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Palisade Bio, Inc.|PALI - Operating income before deduction of amortization|Earnings per share for the last twelve months Palisade Bio|PALI - Earnings per share for the last 12 months|Quarterly EPS earnings growth palisadebio.com|PALI - Net earnings per share growth this year|Expected earnings per share growth for next year Palisade Bio, Inc.

- sales volume and revenue indicators:

PALI - Company Gross Revenue|Company Projected Revenue Palisade Bio|PALI - Price-to-Sales Ratio|Forward P/S Multiple Palisade Bio, Inc.

Initial company analysis:Palisade Bio, Inc. (PALI)

The forward P/S ratio reflects the proportion between current market capitalization and projected sales volume, allowing investors to identify the risk of overpaying amid inflated market expectations. Analyzing the forward price-to-sales ratio helps evaluate the value management efficiency of Palisade Bio, Inc. (PALI), whose narrow specialization in AI-driven molecule selection for gastrointestinal treatment minimizes generic pressure and justifies a premium asset valuation.

Key competitors

Price-to-Projected Revenue Ratio Phathom Pharmaceuticals, Inc. PHAT|Terns Pharma - Price-to-Projected Revenue Ratio|Ironwood Pharmaceuticals Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Curanex Pharmaceuticals Inc CURX|immuron.com.au (IMRN) - Price-to-Projected Revenue Ratio|EVOK - Market Cap to Expected Sales Ratio|ENTO (Entero Therapeutics Inc.) - Forward P/S Multiple|Forward P/S Multiple RedHill|Forward P/S Multiple JAGX|Biora Therapeutics, Inc - Market Cap to Projected Revenue|Forward P/S Multiple MORF (Morphic Holding, Inc.)